Paper Details

  1. Home
  2. Paper Details

Lubiprostone: chronic constipation and irritable bowel syndrome with constipation.

Author: CheyWilliam D, LacyBrian E

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Lubiprostone, a bicyclic fatty acid metabolite analog of prostaglandin E1, is FDA-approved for treating chronic constipation in men and women and women with irritable bowel syndrome with constipation (IBS-C). Lubiprostone specifically activates type-2-chloride channels on the apical membrane of epithelial cells, acting locally within the intestinal tract. It is rapidly metabolized and has very low systemic bioavailability. Animal studies have shown that lubiprostone increases gastrointestinal fluid secretion in a dose-dependent manner. Clinical studies in men and women with chronic constipation using 24 microg of lubiprostone twice daily demonstrated objective improvements in stool frequency and consistency, as well as symptoms of straining and incomplete evacuation. A multicenter study in patients with IBS-C found that 8 microg of lubiprostone twice daily improved both global and individual symptoms of IBS. Lubiprostone is generally well-tolerated, with serious adverse events being rare. The most common reported side effects are nausea, headache, and diarrhea. This monograph provides an overview of chloride channel function in the gastrointestinal tract, describes the structure, function, and pharmacokinetics of lubiprostone, and discusses the safety and efficacy of this new medication for treating chronic constipation and IBS-C.
Paper Details　
Original Abstract of the Article :
Lubiprostone is a bicyclic fatty acid metabolite analogue of prostaglandin E1. The FDA has approved lubiprostone for the treatment of chronic constipation in men and women and the treatment of women with irritable bowel syndrome with constipation (IBS-C). Lubiprostone specifically activates type-2-c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/14656560802631319

データ提供：米国国立医学図書館（NLM）

Lubiprostone: A New Oasis in the Desert of Constipation and Irritable Bowel Syndrome

Constipation and irritable bowel syndrome (IBS), common gastrointestinal disorders, are like a desert wind, causing discomfort and disrupting daily life. This study explores the potential benefits of lubiprostone, a new medication, for the treatment of chronic constipation and IBS with constipation (IBS-C).

The researchers conducted a series of clinical studies to evaluate the efficacy and safety of lubiprostone in patients with chronic constipation and IBS-C. They analyzed the data, focusing on the impact of lubiprostone on stool frequency, consistency, and symptom relief.

Lubiprostone: A Potential Solution in the Desert of GI Disorders

The results of this study are promising, showing that lubiprostone is effective in improving stool frequency and consistency, as well as relieving symptoms associated with chronic constipation and IBS-C. The researchers found that lubiprostone is generally well-tolerated, with minimal side effects.

Navigating the Sand Dunes of Digestive Health

This study offers a potential new weapon in the fight against constipation and IBS-C. Lubiprostone, with its proven efficacy and favorable side effect profile, could provide a valuable option for patients seeking relief from these challenging conditions.

Dr.Camel's Conclusion

This study underscores the potential of lubiprostone as a valuable tool for managing chronic constipation and IBS-C. The researchers' findings offer a beacon of hope for patients seeking relief from these often uncomfortable conditions. This research, like a camel caravan finding a refreshing oasis in a desert, reminds us that there are often effective solutions waiting to be discovered, even in the face of digestive discomfort.

Date :
  1. Date Completed 2009-05-18
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

19236188

DOI: Digital Object Identifier

10.1517/14656560802631319

Related Literature

Article Analysis
・Side Effects of lubiprostone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.